24. Copyright 2016 24Hsiang-Wen Tseng
Global Market For Botanical And Plant-Derived
Drugs To Reach $26.6 Billion In 2017
Source: BCC Research, 2013
Botanical drugs are expected to have a value of $10 million in 2012 and $599 million in 2017,
a CAGR of 126.7%.
All other plant-derived drugs should total $22.1 billion in 2012 and $26.6 billion in 2017, a
CAGR of 3.7%.
25. Copyright 2016 25Hsiang-Wen Tseng
Regulation of Botanical Drugs
Product in USA
OTC (over-the-counter) Drug Monograph:
The OTC drug review is a three-phase public rulemaking
process resulting in the establishment of standards
(monographs or non-monographs) for an OTC
therapeutic drug category.
These standards provide the marketing conditions for
some OTC drug products including the active
ingredients, labeling, and other general requirements.
For a botanical drug substance to be included in an OTC
monograph, there must be published data establishing a
general recognition of safety and effectiveness,
including the results of adequate and well-controlled
clinical studies.
26. Copyright 2016 26Hsiang-Wen Tseng
Regulation of Botanical Drugs
Product in USA
NDA(new drug application):
Under current regulations, if there is no marketing history in the
U.S. or a foreign country for a botanical drug product, if available
evidence of safety and effectiveness does not warrant inclusion of
the product in an OTC drug monograph, or if the proposed
indication would not be appropriate for nonprescription use, the
manufacturer must submit an NDA to obtain FDA approval to
market the product for the proposed use.
An NDA for a botanical drug could seek approval for either
prescription or OTC use, depending on the indication and
characteristics of the product and whether it is safe for use
outside of the supervision of a practitioner licensed by law to
administer it.
An NDA must contain substantial evidence of effectiveness
derived from adequate and well-controlled clinical studies,
evidence of safety, and adequate chemistry, manufacturing, and
controls (CMC) information.
The format of an NDA submission and the requirements for its
various sections are set forth in 21 CFR 314 and discussed in
several CDER guidances.
27. Copyright 2016 27Hsiang-Wen Tseng
1997/4
FDA Guidance
on Botanical
Products
(Draft)
2004/6
Guidance for
Industry
Botanical
Drug
Products
2009/3 植
物藥新藥臨
床試驗基準
2012/4 植物
藥新藥查驗
登記審查基
準
2015/8
Guidance
for Industry:
Botanical
Drug
Products
植物新藥法規發展歷程
(USA and TW)
28. Copyright 2016 28Hsiang-Wen Tseng
FDA’s CDER’s thinking on
development plans for botanical
drugs submitted in new drug
applications (NDAs).
also presents recommendations
for submitting investigational new
drug applications (INDs) and may
also apply to biologics license
applications (BLAs).
Information on the over-the-
counter (OTC) drug monograph
system for botanical drugs.
FDA defines botanicals as
“products that include plant
materials, algae, macroscopic
fungi, and combinations thereof.
Clinical trial: initial (P1/P2) and
expanded (P3)
40. Copyright 2016 40Hsiang-Wen Tseng
Solanum incanum extract (SR-T100) induces human cutaneous squamous
cell carcinoma apoptosis through modulating tumor necrosis factor
receptor signaling pathway
Journal of dermatological science 63(2):83-92 ·April 2011
Therapeutic effects of SR-T100 gel on UVB-induced papillomas (乳頭狀瘤) and MISCCs (微小鱗狀細胞癌, microinvasive squamous cell
carcinoma) in hairless mice. All papillomas disappeared within 11 days of topical SR-T100 gel treatment (A and B), and 90% (27/30) of
MISCCs were cleared within 10 weeks of topical SR-T100 gel treatment (A–C). In controls, none of the tumors disappeared in mice treated
with the base gel only (A: arrowheads and D), and 88% of them (30/34) became larger (D and E). Remarkably, there were no apparent adverse
effects on the perilesional normal skin, following topical use of both SR-T100 and the base gel. After cure of tumors, only slight atrophy of
skin was noted (A; arrows).
41. Copyright 2016 41Hsiang-Wen Tseng
Therapeutic effect of topical SR-T100 gel on human actinic keratosis (AK). A
representative human AK lesion (patient no. 5) was cleared after 16 weeks of topical
treatment with SR-T100 gel. Importantly, SR-T100 gel did not cause damage to the
perilesional normal skin following once daily application for 16 weeks.
Journal of dermatological science 63(2):83-92 ·April 2011